Section Arrow
Quote
PRAX.NASDAQ
- Praxis Precision Medicines
Quotes are at least 15-min delayed:2025/06/04 13:12 EDT
Last
 41.41
+0.21 (+0.51%)
Day High 
42.665 
Prev. Close
41.2 
1-M High
41.27 
Volume 
134.20K 
Bid
41.05
Ask
41.43
Day Low
41 
Open
41.26 
1-M Low
34.8925 
Market Cap 
839.20M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 38.44 
20-SMA 37.92 
50-SMA 36.1 
52-W High 91.83 
52-W Low 26.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-10.66/-19.37
Enterprise Value
839.31M
Balance Sheet
Book Value Per Share
21.56
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
8.55M
Operating Revenue Per Share
0.09
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CLRBCellectar Biosciences0.448+0.1704+61.38%-- 
NCNANuCana plc0.04625-0.01355-22.66%-- 
RXRXRecursion Pharmaceuticals5.0201+0.6301+14.35%-- 
HOTHHoth Therapeutics1.29+0.3702+40.25%-- 
SGMTSagimet Biosciences4.08+0.45+12.40%-- 
Quotes are at least 15-min delayed：2025/06/04 13:12 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized bya neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.